Brokerages Anticipate AEterna Zentaris Inc. (AEZS) to Post ($0.25) Earnings Per Share

Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus target price of $3.00 for the company and are anticipating that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 86 out of 255 based on the ratings given to related companies.

A number of analysts recently issued reports on AEZS shares. Zacks Investment Research raised shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Tuesday, October 9th. ValuEngine downgraded shares of AEterna Zentaris from a “hold” rating to a “sell” rating in a research report on Friday, August 10th.

Shares of AEZS stock opened at $1.46 on Friday. The stock has a market cap of $25.15 million, a PE ratio of -1.08 and a beta of 1.25. AEterna Zentaris has a 1-year low of $1.12 and a 1-year high of $3.25.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.16. The business had revenue of $0.17 million for the quarter. AEterna Zentaris had a net margin of 6.76% and a return on equity of 20.71%. As a group, research analysts anticipate that AEterna Zentaris will post 0.05 earnings per share for the current year.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Read More: Discount Rate

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.

Leave a Reply